BUEMI, MARIAROSA
 Distribuzione geografica
Continente #
NA - Nord America 898
EU - Europa 730
AS - Asia 241
AF - Africa 2
SA - Sud America 1
Totale 1.872
Nazione #
US - Stati Uniti d'America 898
IE - Irlanda 254
SE - Svezia 229
CN - Cina 212
IT - Italia 136
FI - Finlandia 29
IN - India 23
BE - Belgio 21
DE - Germania 18
GB - Regno Unito 18
UA - Ucraina 18
VN - Vietnam 3
JP - Giappone 2
MA - Marocco 2
RO - Romania 2
AT - Austria 1
CL - Cile 1
FR - Francia 1
GR - Grecia 1
MY - Malesia 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 1.872
Città #
Dublin 254
Chandler 190
Nyköping 168
Beijing 87
Ashburn 84
Ann Arbor 75
Jacksonville 69
Messina 68
Princeton 40
Medford 36
Cambridge 33
Des Moines 26
Dearborn 23
Jinan 23
Boardman 20
Brussels 19
Hyderabad 16
San Mateo 14
Shenyang 14
Wilmington 14
Catania 11
Ningbo 11
Woodbridge 11
Francofonte 10
Fuzhou 8
Haikou 8
Seattle 8
Taizhou 8
Pune 7
Guangzhou 6
Hangzhou 6
Hebei 6
Jiaxing 6
New York 6
Tianjin 6
Lancaster 5
Nanjing 5
Nanchang 4
Washington 4
Chicago 3
Clearwater 3
Ho Chi Minh City 3
Houston 3
Rome 3
Borghetto Santo Spirito 2
Carugate 2
Fiorenzuola D'arda 2
Guspini 2
Shanghai 2
Taiyuan 2
Torino 2
Zhengzhou 2
Acton 1
Agadir 1
Athens 1
Austin 1
Brooklyn 1
Chatsworth 1
Dalian 1
Den Haag 1
Halle 1
Hanover 1
Helsinki 1
Jeffries 1
Milan 1
Norwalk 1
Novokuznetsk 1
Palermo 1
Parma 1
Petaling Jaya 1
Prato 1
Qingdao 1
Rende 1
Sassari 1
Tappahannock 1
Vienna 1
Xiangfen 1
Totale 1.465
Nome #
Chemical exploration of 4-(4-fluorobenzyl)piperidine fragment for the development of new tyrosinase inhibitors 94
Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases 91
Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments 84
Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms 77
Graphene Quantum Dots Based Systems As HIV Inhibitors 76
Design and optimization of isoquinoline-sulfonamides as potent and selective inhibitors of human carbonic anhydrase VII 67
Synthesis, biological evaluation and docking studies of NR2B/NMDA receptor antagonists 66
DISCOVERY OF NEW INDOLE DERIVATES AS NEUROPROTECTIVE AGENTS 65
InVivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents 64
Nuovi ligandi del recettore NR2B/NMDA a struttura indolica 62
Serendipitous discovery of indole derivatives as potent tyrosinase inhibitors 59
Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety 57
Searching for NR2B/NMDA Receptor Antagonists As Neuroprotective Agents 56
New indole derivatives as promising ligands for ifenprodil site of NR2B/NMDA receptors 56
Probing the molecular interactions between the human Carbonic Anhydrases (hCAs) and a novel class of benzenesulfonamides 56
Discovery and optimization of isoquinoline-derived inhibitors of human Carbonic Anhydrases (hCAs) 56
Progettazione e sintesi di antagonisti non competitivi del recettore NR2B/NMDA 50
Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis 50
Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides 49
Synthesis and biological characterization of novel potent arylsulfonamides as human carbonic anhydrase inhibitors (hCAIs) targeting central nervous system 46
Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors 45
Discovery of a new potent inhibitor of mushroom tyrosinase (Agaricus bisporus) containing 4-(4-hydroxyphenyl)piperazin-1-yl moiety 45
Synthesis and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-Containing N-Methyl-d-aspartate Receptors 44
Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase 43
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains 43
Design, Synthesis and Biostructural Characterization of Carbonic Anhydrase Inhibitors 42
Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives 42
Identification of 3-substituted-1H-indoles as ligands of GluN2B containing N-methyl-D-aspartate receptors 40
From NMDA receptor antagonists to discovery of selective σ2 receptor ligands 39
SYNTHESIS AND BIOLOGICAL CHARACTERIZATION OF NEW NR2B/NMDA RECEPTOR LIGANDS 37
SYNTHESIS AND BIOLOGICAL CHARACTERIZATION OF 3-SUBSTITUTED-1H-INDOLES AS LIGANDS OF GLUN2B-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS 36
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies 36
Synthesis, Modelling and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-containing N-Methyl-d-Aspartate Receptors 36
Rational design, synthesis and evaluation of coumarin derivatives as protein-protein interaction inhibitors 36
Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening 35
Targeting GluN2B-containing N-Methyl-D-aspartate receptors: design, synthesis, and binding affinity evaluation of novel 3-substituted indoles. 26
Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-d-aspartate receptor (NMDAR) containing GluN2B subunit 25
Rational Design and synthesis of new GluN2B/NMDA receptor ligands as neuroprotective agents. 24
Synthesis and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-containing N-Methyl-D-Aspartate Receptors. Part. 2. 23
Totale 1.978
Categoria #
all - tutte 6.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.903


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 0 8 4
2019/2020200 11 4 4 6 1 26 19 7 6 70 40 6
2020/2021274 15 6 54 11 29 12 11 45 31 40 10 10
2021/2022341 4 54 2 19 1 1 46 16 5 8 106 79
2022/2023730 46 65 33 75 57 61 14 30 328 2 16 3
2023/2024173 11 25 9 48 11 44 0 8 0 17 0 0
Totale 1.978